Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?

Berger PB, Williams JB, Hasselblad V, Chiswell K, Pieper KS, Califf RM.

J Interv Cardiol. 2013 Apr;26(2):123-30. doi: 10.1111/j.1540-8183.2013.12020.x. Epub 2013 Feb 5.

PMID:
23379785
[PubMed - indexed for MEDLINE]
3.

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.

N Engl J Med. 2001 Jun 21;344(25):1888-94.

PMID:
11419425
[PubMed - indexed for MEDLINE]
Free Article
4.

Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.

Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R; STRATEGY Investigators.

JAMA. 2005 May 4;293(17):2109-17.

PMID:
15870414
[PubMed - indexed for MEDLINE]
5.

Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R; Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators.

JAMA. 2008 Apr 16;299(15):1788-99. doi: 10.1001/jama.299.15.joc80026. Epub 2008 Mar 30.

PMID:
18375998
[PubMed - indexed for MEDLINE]
6.

Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.

Mukherjee D, Topol EJ, Bertrand ME, Kristensen SD, Herrmann HC, Neumann FJ, Yakubov SJ, Bassand JP, McClure RR, Stone GW, Ardissino D, Moliterno DJ; TARGET Investigators.

Eur Heart J. 2005 Dec;26(23):2524-8. Epub 2005 Aug 17.

PMID:
16107485
[PubMed - indexed for MEDLINE]
Free Article
7.
8.

Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.

Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Wolski K, DiBattiste PM, Topol EJ.

Circulation. 2002 May 21;105(20):2347-54.

PMID:
12021219
[PubMed - indexed for MEDLINE]
Free Article
9.

Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).

Taglieri N, Saia F, Guiducci V, Tondi S, Conrotto F, Marrozzini C, Rocchi G, Biagini E, Reggiani ML, Giacometti P, Piovaccari G, Manari A, Marzocchi A; FATA Trial Investigators.

Am J Cardiol. 2009 Mar 15;103(6):785-90. doi: 10.1016/j.amjcard.2008.11.029. Epub 2009 Jan 21.

PMID:
19268732
[PubMed - indexed for MEDLINE]
10.

Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.

Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, Neumann FJ, Ardissino D, Bassand JP, Borzi L, Yeung AC, Harris KA, Demopoulos LA, Topol EJ; TARGET investigators.

Lancet. 2002 Aug 3;360(9330):355-60.

PMID:
12241774
[PubMed - indexed for MEDLINE]
11.

Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.

Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D.

Circulation. 2004 May 11;109(18):2203-6. Epub 2004 Apr 26.

PMID:
15117843
[PubMed - indexed for MEDLINE]
Free Article
12.

Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.

Brown DL, Fann CS, Chang CJ.

Am J Cardiol. 2001 Mar 1;87(5):537-41.

PMID:
11230835
[PubMed - indexed for MEDLINE]
13.

Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.

Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann HC, Bertrand M, Harris KE, Demopoulos LA, Topol EJ; TARGET Investigators.

Circulation. 2002 Jun 11;105(23):2730-6.

PMID:
12057986
[PubMed - indexed for MEDLINE]
Free Article
15.

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators.

Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25.

PMID:
12939213
[PubMed - indexed for MEDLINE]
Free Article
16.

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ.

Circulation. 1998 Aug 25;98(8):734-41.

PMID:
9727542
[PubMed - indexed for MEDLINE]
Free Article
17.

Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.

Marmur JD, Poludasu S, Lazar J, Cavusoglu E.

Catheter Cardiovasc Interv. 2009 Feb 1;73(2):214-21. doi: 10.1002/ccd.21773.

PMID:
19156882
[PubMed - indexed for MEDLINE]
18.

A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.

Circ Cardiovasc Interv. 2009 Jun;2(3):230-6. doi: 10.1161/CIRCINTERVENTIONS.108.847996. Epub 2009 Apr 21.

PMID:
20031720
[PubMed - indexed for MEDLINE]
Free Article
19.

Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.

Gunasekara AP, Walters DL, Aroney CN.

Int J Cardiol. 2006 Apr 28;109(1):16-20. Epub 2005 Jul 12.

PMID:
16014315
[PubMed - indexed for MEDLINE]
20.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

PMID:
10208997
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk